1992 Postdoctoral Diploma of Specialist, University of Bologna, Infectious Diseases
-
D. De Ronchi, I. Faranca, D. Berardi, P. Scudellari, M. Borderi, R. Manfredi, L. Fratiglioni. Risk factors for cognitive impairment in HIV-1-infected persons with different risk behaviors. Archives of Neurology 2002; 59: 812-818.
-
R. Manfredi, R. Motta, D. Patrono, L. Calza, F. Chiodo, P. Boni. A prospective case-control survey of laboratory markers of skeletal muscle damage during HIV disease and antiretroviral therapy. AIDS 2002; 16:1969-1972; erratum in AIDS 2003; 17: 145.
-
L. Calza, R. Manfredi, F. Chiodo. Statins and fibrates for the treatment of hyperlipidaemia in HIV-infected patients receiving HAART. AIDS 2003; 17:851-859.
-
R. Manfredi. HIV infection, antiretroviral therapy, and hepatic function. Emerging epidemiological, pathogenetic, and clinical issues, and their consequences on disease management. AIDS 2003; 17: 2253-2256.
-
R. Manfredi., A. Nanetti, M. Tadolini, L Calza, S. Morelli, M. Ferri, G. Marinacci. Role of Mycobacterium xenopi disease in patients with HIV infection at the time of highly active antiretroviral therapy (HAART), Comparison with the pre-HAART period. Tuberculosis 2003; 83: 319-328.
-
L. Calza, R. Manfredi, F. Chiodo. Infective endocarditis: a review of the best treatment options. Expert Opinion on Pharmacotherapy 2004; 5: 1899-1916.
-
R. Manfredi. HIV infection and advanced age. Emerging epidemiological, clinical, and management issues. Ageing Research Reviews 2004; 3: 31-54.
-
R. Manfredi, L. Calza, F. Chiodo. Efavirenz versus nevirapine in current clinical practice: a prospective, open-label observational study. Journal of Acquired Immune Deficiency Syndromes 2004; 5: 492-502.
-
R. Manfredi, A. Nanetti, R. Valentini, M. Ferri, S. Morelli, L. Calza. Epidemiological, clinical and therapeutic features of AIDS-related Mycobacterium kansasii infection during the HIV pandemic: an 11-year follow-up study. HIV Medicine 2004; 5: 431-436.
-
R. Manfredi, L. Calza, F. Chiodo. Changing epidemiology of hepatitis A in tbe Bologna metropolitan area, northern Italy: importance of conselling and prophylactic mesures for the male homo/bisexual population. Clinical Microbiology and Infection 2005; 11: 845-848.
-
R. Manfredi. High-risk dysmetabolism disorders associated with HAART-treated HIV disease, and reimbursement of lipid-lowering drugs, in a clinical and socio-economic perspective. AIDS Reviews 2005; 7: 155-160.
-
R. Manfredi, S. Sabbatani. A novel antiretroviral class (Fusion Inhibitors) in the management of HIV infection. Present features and future perspectives of Enfuvirtide (T-20). Current Medicinal Chemistry 2006; 13: 2369-2384.
-
R. Manfredi, L. Calza, F. Chiodo. Primary Cytomegalovirus infection in otherwise healthy adults with fever of unknown origin: a 3-year prospective survey. Infection 2006; 34: 87-90.
-
R. Manfredi, L. Calza, F. Chiodo. Prolonged statin administration does not act on the cell-mediated immunity of HIV-infected dyslipidemic patients treated with a steady and effective highly active antiretroviral therapy. A two-year prospective study of statin versus fibrate administration, versus a dietary/exercise program. Journal of Biological Regulators and Homeostatic Agents 2006; 20: 1-9.
-
R. Manfredi, S. Sabbatani, S. Bergonzi. Clinical ritonavir and lopinavir hypersensitivity confirmed by a specific in vitro cellular allergen stimulation test. Current HIV Research 2007; 5: 440-442.
-
R. Manfredi, L. Calza. Recent availability of two novel, fixed formulations of antiretroviral nucleoside analogues: a 12-month prospective, open-label survey of their practical use and therapeutic perspectives on antiretroviral-naïve and -experienced patients. AIDS Patient Care and STDs 2008; 22: 279-290.
-
L. Calza, R. Manfredi, D. Pocaterra, F. Chiodo. Risk of premature atherosclerosis and ischemic heart disease associated with HIV infection and antiretroviral therapy. Journal of Infection 2008; 57: 16-32.
-
R. Manfredi, G. Marinacci, L. Calza, B. Passarini. Diffuse cutaneous dissemination of visceral leishmaniasis during human immunodeficiency virus (HIV) infection, despite negligible immunodeficiency: repeated failure of liposomal amphotericin B administration, followed by successful long-term pentamidine and paromomycin administration. International Journal of Antimicrobial Agents 2008; 31: 590-592.
-
R. Manfredi. Multicentre inter-cohort studies – reliable responses for HIV disease management? AIDS Reviews 2009; 11: 53-55.
-
L. Calza, R. Manfredi, V. Colangeli, D. Pocaterra, N. Rosseti, M. Pavoni, F. Chiodo. Efficacy and safety of atazanavir-ritonavir plus abacavir-lamivudine or tenofovir-emtricitabine in patients with hyperlipidaemia switched from a stable protease inhibitor-based regimen including one thymidine analogue. AIDS Patient Care and STDs 2009; 23: 691-697.
-
R. Manfredi, A. Nanetti, P. Dal Monte, L. Calza. Increasing pathomorphism of pulmonary tuberculosis: an observational study of slow clinical, microbiological and imaging response of lung tuberculosis to specific treatment. Which role for linezolid? Braz J Infect Dis. 2009; 13: 297-303.
-
L. Calza, R. Manfredi R, G. Verucchi. Myocardial infarction risk in HIV-infected patients: epidemiology, pathogenesis, and clinical management. AIDS. 2010; 24: 789-802.
-
L. Calza, R. Manfredi. Protease inhibitor monotherapy as maintenance regimen in patients with HIV infection. Curr HIV Research 2012; 10: 661-672.
-
L. Calza, F. Trapani, C. Salvadori, E. Magistrelli, R. Manfredi, V. Colangeli, M.A. Di Bari, M. Borderi, P. Viale. Incidence of renal toxicity in HIV-infected, antiretroviral-naïve patients starting tenofovir/emtricitabine associated with efavirenz, atazanavir/ritonavir, or lopinavir/ritonavir. Scandinavian Journal of Infectious Diseases 2013; 45: 147-154.
-
L. Calza, R. Manfredi, V. Colangeli, F.F. Trapani, C. Salvadori, E. Magistrelli, I. Danese, G. Verucchi, C. Serra, P. Viale. Two-year treatment with rosuvastatin reduces carotid intima-media thickness in HIV type 1-infected patients receiving highly active antiretroviral therapy with asymptomatic atherosclerosis and moderate cardiovascular risk. AIDS Research and Human Retroviruses 2013; 29: 547-56.